HCM
ALXN

Herndon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Herndon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-21
Closed -$3K – 577
2016
Q3 		$3K Hold
21
– – ﹤0.01% 334
2016
Q2 		$2K Buy
+21
New +$2.98K ﹤0.01% 421

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Herndon Capital Management's ALXN Position: Q4 2016 in Review

Herndon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 21 shares — an estimated $3K sold.

Herndon Capital Management first reported a position in ALXN in Q2 2016 and held it in 2 quarters. The position peaked at $3K in Q3 2016. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • Herndon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Herndon Capital Management sold 21 Alexion Pharmaceuticals shares in Q4 2016, an estimated $3K.
  • Herndon Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Herndon Capital Management's Alexion Pharmaceuticals position peaked at $3K in Q3 2016.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Herndon Capital Management's 13F filing for Q4 2016, filed 2 Feb 2017.